Lenskart shares climbed nearly 3% on Friday after JPMorgan initiated coverage on the eyewear retailer with an 'Overweight' rating and target price of ₹635, lifting the stock close to its 52-week high. The stock rose as much as 2.72% to an intraday high of ₹560, just below its 52-week high of ₹562.70. At around 10 a.m., the shares were trading 1.50% higher at ₹553.35 apiece, with the BSE Sensex up 1.05% at 77,544. According to CNBC TV18, the brokerage expects operating leverage to drive 33% EBITDA CAGR over FY26-30, supported by volume growth, premiumisation, and rising Gold member salience.
JPMorgan initiated coverage on Lenskart with an 'Overweight' rating and September '27 target price of ₹635, citing the company's scalable and profitable business model. As reported by CNBC TV18, analysts Latika Chopra, Himanshu Singh and Saransh S Gokhale noted that Lenskart has evolved into a scalable, profitable operating model serving widespread and rising eyecare needs across India and select overseas markets. The brokerage expects the company's international operations to emerge as a second growth engine, with overseas revenue and EBITDA salience at 42% and 26% respectively in FY26. JPMorgan described the business as positioned to gain market share in the eyewear industry and identified volume growth, premiumisation, increasing contribution of high-retention Gold members, and operating leverage as key positives.
Brokerages maintain constructive views on TCS despite mixed quarterly results, with Choice Institutional Equities joining the bullish camp with a Buy rating and target of ₹2320 in its latest report dated July 10, 2026. Motilal Oswal maintains Buy with a target of ₹2350, while Nuvama has revised its target to ₹3000 from ₹3350 and Emkay maintains Add with a target of ₹2600. According to latest reports from ET Now, Goldman Sachs has also maintained Buy with a revised target of ₹2370 from ₹2410, citing the company as a solid operator in a difficult transition. JPMorgan maintains Overweight with a target of ₹2400, noting minor revenue beat led by India operations. The latest Choice Institutional Equities report highlights that TCS reported a largely in-line Q1FY27 with stable revenue despite challenging macro conditions, with BFSI and Technology sectors supporting growth while Consumer and Manufacturing remained weak.
Emkay has maintained a Buy rating on Dixon Technologies with a revised target price of ₹15,200, following the latest corporate developments. As reported by ET Now, this upgrade reflects the company's strong fundamentals and growth trajectory. The brokerage expects Dixon to return to high-growth status for the next two years, with FY27 mobile volume guidance likely to be raised despite margin dilution. This drives a 24-39% upgrade to revenue estimates over FY27-29E and 13-18% EPS estimate upgrade.
Multiple brokerages maintain mixed views on Dr. Reddy's Laboratories amid ongoing API supply issues. Nuvama has maintained Buy with a revised target of ₹1465 from ₹1560, while Emkay maintains Reduce with a target of ₹1300. As reported by ET Now, DAM Capital maintains Neutral with a target of ₹1259, and Citi maintains Sell with a target of ₹1070. The company faces Semaglutide API impurity issues that may partially squander early mover advantage, with estimated Semaglutide Canada sales of $56 million in FY27 and $38 million in FY28. Jefferies maintains Underperform with a target of ₹1040, noting scale-up issues pushing commercialisation to October/November. The company's focus on ex-US business revenue growth and gross margin recovery after tepid Q4FY26 performance remains crucial for future performance.
